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but no known CAD. J Am Coll Cardiol 2004;43:200–8.A Randomized Trial Comparing 1 mg of Oral Vitamin K With No Treatment in the
y in Patients With Mechanical Heart Valveso the Editor: A strong relationship exists between the risk of
emorrhage and the degree of prolongation of the international
ormalized ratio (INR) in patients receiving warfarin, particularly
hen the INR exceeds 6.0 (1). Simply withholding warfarin is
ikely to be associated with a low, but clinically important, risk of
ajor or life-threatening hemorrhage (1,2). The oral administra-
ion of low doses of vitamin K has been shown to safely and
ffectively reduce the INR toward the normal range in patients
resenting with INR values 4.5 (3–5). In patients with mechan-
cal heart valves, there is a safety concern with the use of vitamin
because overcorrection of the INR may cause thrombosis. The
urpose of this study was to demonstrate that the oral adminis-
ration of low-dose vitamin K is an effective and safe treatment for
atients with mechanical heart valves who present with excessive,
arfarin-associated, anticoagulant effect.
Patients with mechanical heart valves who were receiving
arfarin therapy and who presented with INR values between 6.0
nd 12.0 were allocated randomly to receive either 1 mg of vitamin
administered orally (Phytomenadione, Konakion, Roche, Milan,
taly, or Phytonadione, Mephyton, Merck & Co. Inc., West Point,
ennsylvania) or no treatment. Patients were excluded in the
resence of elevated INR value determined more than 12 h before
creening; high risk of hemorrhage; major non-orthopedic surgery
ithin the past week; thrombocytopenia (platelet count 50 
09/l); indication for acute reversal of anticoagulation; termination
f anticoagulation; receipt of vitamin K or plasma in the 48-h
eriod before enrollment; allergy or sensitivity to vitamin K or
lasma or other contraindication to vitamin K therapy; severe liver
isease; geographic inaccessibility or inability to comply with
equirements for blood work; or failure to obtain informed
onsent.
The day of randomization and study drug administration was
efined as day 0. All patients underwent INR measurement on the
ay after study intervention (day 1). We determined INR values
sing standard local laboratory techniques. In particular, the
ollowing thromboplastin reagents were used: Innovin by Dade
ehring (Milan, Italy; ISI 1.03) at study locations in Varese and in
eggio Emilia, Italy, and Neoplastine by Diagnostica Stago
Parsipanny, New Jersey; ISI 1.27) at the study location in
lbuquerque, New Mexico.
Warfarin therapy was restarted once the INR was in the target
ange, as determined by the attending physician. Patients were
linically followed-up on day 5  1 and were subsequentlyo determine whether thromboembolic or hemorrhagic events had
ccurred.
Analysis was based on the principle of intention to treat. For the
rimary analysis, the proportion of patients with INR values
etween 2.3 and 3.7 on day 1 was determined and compared using
he Fisher exact test. The primary safety analysis was an analysis of
he number of patients who received vitamin K who developed an
NR value of 1.8 on day 1 and also was performed using the
isher exact test. The value of 1.8 was chosen as a “lower limit” for
he INR because this represents a value below which many
hysicians would be concerned that there is a substantially in-
reased risk of thromboembolism. Baseline data were compared
sing the Student t test.
We calculated that we would need to enroll 48 patients per arm
o reliably demonstrate that oral vitamin K was more effective than
imple warfarin withdrawal. We assumed a binomial distribution
nd conservative “success” rates of 40% and 10% in the “oral
itamin K” and “no treatment” arms, respectively, because a sample
ize of 96 would be adequate to achieve power of 90% and alpha
.05. Institutional review board approval was obtained at all
articipating centers.
Between September 2002 and October 2004, 59 patients
rovided informed consent for the study. In October 2004, the
tudy was prematurely stopped because a multinational study
xamining the utility of oral vitamin K, using clinical end points as
able 1. Baseline Characteristics
Vitamin K No Treatment p Value
umber 29 30 —
ean age (yrs) 66 63 NS
ge range (yrs) 31–88 30–83 —
ales 16 11 NS
utpatients 29 30 —
itral prosthetic valve 13 16 NS
ortic prosthetic valve 17 16 NS
itral and aortic
position
1 2 NS
oncomitant atrial
fibrillation
10 9 NS
oncomitant heparin
treatment
0 0 NS
revious bleeding 7 5 NS
revious asymptomatic
INR elevation
20 18 NSNR  international normalized ratio; NS  not significant.
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August 16, 2005:730–42he primary outcome measure, was initiated. Of the 59 patients, 29
ere assigned randomly to 1 mg of oral vitamin K and 30 were
ssigned to withhold warfarin only. Baseline characteristics are
ummarized in Table 1, and results are summarized in Table 2. No
ajor bleeding events occurred in either group. There was one
pisode of minor bleeding (epistaxis) in the vitamin K group and
o episodes in the control group. One patient died in the vitamin
group because of acute pulmonary edema; no deaths were
ecorded in the control group.
This randomized clinical trial is the first to examine the efficacy
f oral vitamin K in patients with mechanical heart valves.
ompared with “no treatment,” 1 mg of oral vitamin K more
ommonly returned prolonged INR values to the therapeutic or
ear-therapeutic range within one day. Given that major bleeding
an occur in as many as 4% of patients who present with an INR
6.0 who are treated with simple warfarin withdrawal (1), this
nding may be clinically relevant. In our study, only 3.4% of
atients treated with low-dose oral vitamin K had INR values
5.0 at 24 h after administration of the study drug. In contrast,
3.3% of the patients who simply withheld warfarin had INR
alues 5.0 at 24 h after study enrollment (p  0.001).
The administration of vitamin K produced what we defined as
n over-reversal in approximately 10% of patients. The difference
etween the two groups in the proportion of patients with INR
alues 1.8 was not statistically significant, and none of the
atients in this study had thrombotic events during follow-up.
evertheless, such a high proportion of patients with an INR less
han the therapeutic range raises the concern that low-dose oral
itamin K may increase the risk of thromboembolism in this
opulation; we anticipate that the results of our ongoing multina-
ional study will determine whether oral vitamin K, administered
n this setting, is associated with thromboembolism.
Our study had two important limitations. First, we used the
NR, rather than clinical outcomes, as the primary outcome
easure. Although the INR is a validated surrogate marker for
leeding and thrombotic complications in stably anticoagulated
able 2. Study Results
Vitamin K No Treatment p Value
umber 29 30
ean INR day 0 7.22 7.72
ean INR day 1 2.99 5.23
umber of patients with
INR 2.3–4.5 on day 1
13 4 0.001*
umber of patients with
INR 1.8 on day 1
3 0 NS
Odds ratio 5.3, 95% confidence interval 1.3 to 25.5.
Abbreviations as in Table 1.atients, its association with these complications is less clear when
Results From the International Reg
oncomitant CHF has remained largely restricted to case reports
(
u
C
the INR is changing rapidly (for example, during warfarin initia-
ion or after administration of oral vitamin K). Second, this study
as terminated prematurely, and the enrollment target was not
eached. Nonetheless, the observed difference in the primary end
oint was statistically significant. Even if target enrollment had
een reached, it is unlikely that our findings would have had
ufficient power either to detect differences in clinical outcomes or
o demonstrate a statistically rigorous association between oral
itamin K administration and an INR 1.8 on day 1.
In summary, our study provides additional support for the
ypothesis that the administration of 1 mg of oral vitamin K is very
ffective for the treatment of asymptomatic warfarin-associated
oagulopathy in patients presenting with INR values 6.0. Our
nthusiasm for this treatment is, however, tempered by the
bservation that about one in 10 patients who receive vitamin K
ill have an INR of 1.8 on the day following vitamin K
dministration; it is possible that these patients are at risk for
voidable thrombosis.
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istry of Acute Aortic Dissectiono the Editor: Congestive heart failure (CHF) has long been
ecognized as a potential complication of aortic dissection (AoD);
owever, the understanding of the presentation of AoD with1–6). Therefore, we undertook the present analysis to better
nderstand the characteristics and outcomes of patients with acute
HF at the time of AoD, as well as the impact of CHF on the
ime to AoD recognition and treatment.
